基于FIB-4的转诊路径在识别肝脏硬度升高及新发晚期肝病方面准确性欠佳
研究利用NHANES 2017至2020年代谢功能障碍人群(6375例)做横断面分析、AMORIS队列(53766例)做纵向分析,评估基于FIB-4的转诊路径识别肝脏硬度升高(LSM)及国际疾病分类定义的新发晚期肝病的能力。结果显示该路径转诊率高,却漏检约60%的LSM≥8、50%的LSM≥12、40%的LSM≥15及25%的新发晚期肝病。
要点
- 在被认为无临床相关肝病者(72%)中,仍有8.5%为LSM≥8、2.3%为LSM≥12、1.1%为LSM≥15。
- 18至35岁人群中FIB-4对LSM升高的敏感性为0.0%;65至80岁人群转诊率高达71%,采用年龄校正界值时敏感性仅34%。
- 纵向分析中FIB-4检出74%的5年新发晚期肝病(肝硬化或肝细胞癌),但漏检约25%。
核心结论
- 基于FIB-4的普通人群肝病转诊路径导致高转诊率,同时漏检约60%的LSM≥8、50%的LSM≥12、40%的LSM≥15及25%的新发晚期肝病。
- 作者认为,当前在低患病率人群中检测肝硬化前肝病的转诊路径可从进一步优化中获益。
研究设计与样本
- 横断面分析使用美国国家健康与营养调查(NHANES)2017至2020年代谢功能障碍参与者,共6375例,年龄52岁(四分位距36-64岁),男性49%。
- 纵向分析使用载脂蛋白死亡风险(AMORIS)队列,共53766例,年龄54岁(四分位距45-61岁),男性65%,事件132例。
- 研究评估基于FIB-4的转诊路径识别肝脏硬度升高(LSM)和(或)基于国际疾病分类的新发晚期肝病的能力,并纳入年龄校正界值的应用分析。
主要发现
- 横断面人群中10.3%为LSM≥8、3.4%为LSM≥12,28%为FIB-4≥1.3。
- 在被认为无临床相关肝病者(72%)中,LSM≥8、≥12和≥15 kPa者分别占8.5%、2.3%和1.1%。
- 18至35岁参与者中FIB-4对LSM升高的敏感性为0.0%;65至80岁参与者转诊率为71%,采用年龄校正界值时敏感性为34%。
- 纵向分析中FIB-4检出74%的5年新发晚期肝病(肝硬化或肝细胞癌)病例。
关键数值与推荐
- LSM≥8者占10.3%,LSM≥12者占3.4%,FIB-4≥1.3者占28%。
- 无临床相关肝病者中LSM≥8、≥12、≥15 kPa分别占8.5%、2.3%、1.1%。
- FIB-4漏检约60%的LSM≥8、50%的LSM≥12、40%的LSM≥15及25%的新发晚期肝病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Fibrosis-4 (FIB-4) is the cornerstone of identifying clinically relevant liver disease among low-prevalence populations. However, its diagnostic accuracy is debated. METHODS: Participants with metabolic dysfunction from the National Health and Nutrition Examination Survey (NHANES) 2017 to 2020 and Apolipoprotein MOrtality RISk (AMORIS) were used for cross-sectional and longitudinal analysis, respectively. The ability of the FIB-4-based referral pathways to detect individuals with increased liver stiffness (LSM) and/or International Classification of Diseases-based incident advanced liver disease was investigated. Additional analysis included the application of an age-adjusted cutoff. RESULTS: Cross-sectional analysis comprised 6375 participants (age, 52 years [interquartile range, 36-64 years]; 49% male), of whom 10.3% had LSM ≥8, 3.4% LSM ≥12 and 28% FIB-4 ≥1.3. Among those considered to have no clinically relevant liver disease (72%), LSM ≥8, 12, and 15 kPa was still present in 8.5%, 2.3%, and 1.1%, respectively. The FIB-4 had 0.0% sensitivity for increased LSM among participants aged 18 to 35 years and a high referral rate (71%) among participants aged 65 to 80 years or low sensitivity (34%) with the age-adjusted cutoff. However, in the longitudinal analysis (n = 53,766; age, 54 years [interquartile range, 45-61]; male 65%; events 132), FIB-4 detected 74% of 5-year incident cases of advanced liver disease (cirrhosis or hepatocellular carcinoma). CONCLUSIONS: FIB-4-based referral pathways to identify liver disease among the general population result in a high referral rate while not detecting approximately 60% of LSM ≥8, 50% of LSM ≥12, 40% of LSM ≥15, and 25% of incident advanced liver disease. Current referral pathways to detect precirrhotic liver disease in low-prevalence populations could benefit from further optimization.
引用
- van Kleef LA, Strandberg R, Pustjens J, et al. FIB-4-based Referral Pathways Have Suboptimal Accuracy to Identify Increased Liver Stiffness and Incident Advanced Liver Disease. Clin Gastroenterol Hepatol. 2025. PMID: 40712713. doi:10.1016/j.cgh.2025.06.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。